Anzeige
Mehr »
Montag, 02.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 932242 | ISIN: IE0005711209 | Ticker-Symbol: IJF
Tradegate
02.03.26 | 07:47
91,64 Euro
+0,20 % +0,18
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ICON PLC Chart 1 Jahr
5-Tage-Chart
ICON PLC 5-Tage-Chart
RealtimeGeldBriefZeit
91,0291,6408:26
90,4291,6208:25

Aktuelle News zur ICON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHere is Why ICON Public Limited Company (ICLR) Offers an Impressive Upside7
23.02.ClearBridge Global Value Improvers Strategy adds BEP and MKKGY; exits PYPL and ICLR34
18.02.Levi & Korsinsky, LLP: ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement210(NASDAQ: ICLR) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating ICON plc (NASDAQ: ICLR) following the company's disclosure on February...
► Artikel lesen
14.02.ICON Public Limited Company (ICLR) Delays Earnings Amid Internal Investigation12
12.02.Clinical Research Provider Icon Stock Crashes On Accounting Probe63
12.02.ICON PLC - 6-K, Report of foreign issuer24
27.01.ICON Opens New Cancer Institute in Illinois4
ICON Aktie jetzt für 0€ handeln
27.01.ICON plc: ICON's Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership341ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly...
► Artikel lesen
07.01.ICON PLC - 6-K, Report of foreign issuer4
05.01.Artisan Mid Cap Value Fund Increased its Stake in ICON Public Limited Company (ICLR). Here's Why13
17.12.25Here's Why ICON Plc. (ICLR) Gained +20.3% in Q39
09.12.25ICON plc: ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive487ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update...
► Artikel lesen
02.12.25ICON plc: ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions461ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup....
► Artikel lesen
12.11.25ICON plc to Present at the Jefferies London Healthcare Conference355ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies...
► Artikel lesen
12.11.25ICON PLC - 6-K, Report of foreign issuer3
22.10.25ICON PLC: EPS übertrifft Schätzungen um 0,01 $ - Umsatz besser als erwartet18
22.10.25ICON plc: ICON Reports Third Quarter 2025 Results563Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. ...
► Artikel lesen
22.10.25ICON PLC - 6-K, Report of foreign issuer1
21.10.25ClearBridge Select Strategy buys REGN, VRTX & VST; exits ICLR, PCTY & ADBE26
24.09.25ICON plc Schedules Third Quarter 2025 Earnings Conference Call495ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1